Navigation Links
Clampdown On Fake Drugs Manufacturers In India – New Bill Enacte

The Central Government of India is planning to incorporate penal provisions under the Drugs and Cosmetics// (Amendment) Bill 2005 to make licensed drug manufacturers who are in the habit of designing or packing their products in such a look-alike manner a criminal act. Officials say the Bill attempts to bring in imitations or substitutes (look-alike) cases where a drug resembles another drug in such a manner that it could be mistaken for the other drug under the definition of spurious drug and hence proposes stringent penal provisions. They also say that such cases would be non-bailable and would result in 10 years of imprisonment and hefty penalties.

The Bill proposes to enhance the period of imprisonment for manufacture or sale of spurious drugs for a term which shall not be less than ten years, which may be extended to imprisonment for life and a fine of ten lakh rupees or three times the value of the drugs confiscated, whichever is more. It has been proposed to provide for a fine of not less than 20,000 rupees under section 28 for non-disclosure of the name of the manufacturer and under section 28A for not keeping documents, etc., and for not disclosure of information. Subsequent offences would be seriously dealt with.

The existing law provides for punishment for imprisonment not less than two years which may be extended to six years and with fine of not less than rupees ten thousand for manufacture and sale of any adulterated drug or manufacture and sale of drugs without a valid licence. Thus the government has proposed to enhance the said punishment which shall not be less than seven years but which may be extended to ten years and with fine which shall not be less than two lakh rupees.

The Bill also proposes to designate one or more Court of Session as Special Court for trial of offences related to adulterated or spurious drugs. Once the new Bill is passed, offences relating to adulterated or spurious drugs would turn cognizable a
'"/>




Page: 1 2

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Emphasis to ban Drugs ads by Doctors
5. Osteoporosis Drugs: right time to take-off
6. Drugs disrupt formation of blood vessels
7. Drugs to stop burgeon of HIV
8. Misleading Advertisements for Prescription Drugs
9. Drugs For Anthrax May Interfere With Oral Contraceptives
10. Over-The-Counter Drugs May Prevent Alzheimers
11. Steps To Improve Quality Of Plant-Based Drugs
Post Your Comments:
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3
...ts act together to check the perilous trend of twi...artment has suggested a cap on the// embryo, allow...el set in motion by the Human Fertilization and Em... the wrong side of 30. Further IVF clinics w...
...be efficient on animals according to researchers a...ps we can cure HIV infection. This is our hope," s...tario. Clinical trials of the vaccine are expect...e to be careful because we have done the animal, t...
...wn the risk of Alzheimer's disease by reducing inf... recent communiqué. The finding// holds a clue as...in the 1960s and 1970s are at a lesser chance of d...ties of ceasing loss of brain cells, which is a ch...
...ged that AIDS is no more restricted to just risk g...ses are added each day according to statistics wit...bted to be AIDS positive. It is alarming to note t... too has more number of infections being spread th...
... affected only by thalassemia intermedia till Febr... positive.// Initially, blood transfusion wa...rsened, she underwent blood transfusion 10 times l...c kits from the jute baron Govind Sarda's firm; Mo...
...ed by scientists in the US attacks the malaria par...he disease that has kills one million// people a y...veloped by Walter Reed Army Institute of Research ...common, reported the science portal EurekAlert. ...
Other Medicine News:Health News:Thalassemic patient is now HIV positive due to faulty Diagnostic kit… 2
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
Breaking Medicine Technology:Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 1Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 2K State program will give young professionals skills to protect water resources 10693 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 2High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 3High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 4
...Host Conference Call at 9:00 a.m. EDT-, MONTVALE,...aq: MEMY ) today announced top-line data from the...ontrolled Phase 2a study,of MEM 1003, a neuronal L...sease. The trial enrolled 183 subjects with mild t...in the United States and included monotherapy,subj...
...N.J. and NEW YORK, Oct. 12 Daiichi Sankyo,Inc. an...d today that they,have signed a contract for a co-...hi Sankyo,s AZOR(TM), a fixed combination of two,a...odipine and the,angiotensin receptor blocker, olme... letter of intent for the co-promotion agreement o...
Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 2Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 3Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 4
Microalbumin Linearity Control
Total IgE Control
Lyophilized Lipid Control
High-sensitive CRP Control
Medicine Products: